Perry Capital Partners

ShareBite Inc., founded in 2014 and based in New York, operates a mobile application for corporate meal benefits. It facilitates team orders, flexible solutions, centralized allowances, and curated restaurant choices for employees of leading companies across various sectors. Notably, ShareBite integrates social impact by donating a meal to local hunger relief initiatives like Feeding America and City Harvest for every transaction made on its platform.

Loadsmart is a logistics technology company that provides an online platform for shippers and carriers to quote, book, and track freight. The platform aims to move freight quickly and efficiently by offering real-time quotes, automated pricing, and streamlined shipper-carrier interactions. By leveraging technology and logistics data, Loadsmart seeks to optimize pricing, booking, and shipment visibility, delivering transparent, reliable freight services to shippers and carriers. Founded in 2014, the company is based in Chicago, Illinois.

Loadsmart is a logistics technology company that provides an online platform for shippers and carriers to quote, book, and track freight. The platform aims to move freight quickly and efficiently by offering real-time quotes, automated pricing, and streamlined shipper-carrier interactions. By leveraging technology and logistics data, Loadsmart seeks to optimize pricing, booking, and shipment visibility, delivering transparent, reliable freight services to shippers and carriers. Founded in 2014, the company is based in Chicago, Illinois.

Capital Factors is an innovative and leading provider of factoring, credit protection, accounts receivable collection services.

Palatin Technologies, Inc. is a biopharmaceutical company focused on developing targeted, receptor-specific peptide therapeutics to address diseases with significant unmet medical needs. Based in Cranbury, New Jersey, the company’s lead product is Vyleesi, a melanocortin receptor agonist aimed at treating premenopausal women with acquired, generalized hypoactive sexual desire disorder. In addition to Vyleesi, Palatin is advancing several other drug candidates, including oral PL8177 and systemic PL8177 for inflammatory bowel diseases and non-infectious uveitis, respectively. The company also develops PL9643 for ocular inflammatory conditions, PL3994 for cardiovascular issues, and PL5028 for cardiovascular and fibrotic diseases. Palatin's research emphasizes receptor-selective melanocortin agonists, which activate endogenous pathways to mitigate inflammation and promote tissue healing in various disease models, particularly in ocular and intestinal applications.